

EV 506438425 US

PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

|   |   |                          |                   |                        |             |
|---|---|--------------------------|-------------------|------------------------|-------------|
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use as many sheets as necessary) |   | <b>Complete if Known</b> |                   |                        |             |
|   |   | Application Number       | 10/777,488        |                        |             |
|   |   | Filing Date              | February 12, 2004 |                        |             |
|   |   | First Named Inventor     | Adnan M.M. Mjalli |                        |             |
|   |   | Art Unit                 | 1626              |                        |             |
|   |   | Examiner Name            | Laura Stockton    |                        |             |
| Sheet   | 1 | of                       | 1                 | Attorney Docket Number | TTP 2002-08 |

| NON PATENT LITERATURE DOCUMENTS |                          |   |                |
|---------------------------------|--------------------------|---|----------------|
| Examiner<br>Initials *          | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
| LLS                             | TR-226                   | LIPSHUTZ et al., "Metalation Studies of Trisubstituted Oxazoles", Journal of Organic Chemistry, Vol. 46, pages 1410-1413, (1981)  |                |
| LLS                             | TR-225                   | NAKAYAMA et al., "MexAB-OprM-Specific Efflux Pump Inhibitors in Pseudomonas aeruginosa. Part 1: Discovery and Early Strategies for Lead Optimization", Bioorganic & Medicinal Chemistry Letters, Vol. 13, pages 4201-4204, (2003)                               |                |
|                                 |                          |   |                |
|                                 |                          |   |                |
|                                 |                          |   |                |
|                                 |                          |   |                |
|                                 |                          |   |                |
|                                 |                          |   |                |
|                                 |                          |   |                |
|                                 |                          |   |                |
|                                 |                          |   |                |
|                                 |                          |   |                |
|                                 |                          |   |                |

|                       |                     |                    |            |
|-----------------------|---------------------|--------------------|------------|
| Examiner<br>Signature | /Laura L. Stockton/ | Date<br>Considered | 01/18/2007 |
|-----------------------|---------------------|--------------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 841058245 US

PTO/SB/08a (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

## Complete If Known

|                        |                   |
|------------------------|-------------------|
| Application Number     | 10/777,488        |
| Filing Date            | February 12, 2004 |
| First Named Inventor   | Adnan M.M. Mjalli |
| Art Unit               | 1626              |
| Examiner Name          | Laura Stockton    |
| Attorney Docket Number | TTP 2002-08       |

## U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Document Number<br>Number - Kind Code <sup>2</sup> (if known) | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant<br>Passages or Relevant<br>Figures Appear |
|--------------------|-----------------------|---|--------------------------------|---|---|
| LLS                | TR-333                | US- 2005-0014805  | 01/20/2005                     | Zhang et al.                                    |   |
|                    | TR-350                | US- 2004-0188151  | 09/23/2004                     | Mjalli et al.                                   |   |
|                    | TR-351                | US- 2004-0192743  | 09/30/2004                     | Mjalli et al.                                   |   |
|                    | TR-352                | US- 2004-0082542  | 04/29/2004                     | Mjalli et al.                                   |   |
|                    | TR-734                | US- 5,106,732   | 04/21/1992                     | Kondo et al.                                    |   |
|                    | TR-735                | US- 5,510,362   | 04/23/1996                     | Matassa et al.                                  |   |
|                    | TR-736                | US- 5,616,601   | 04/01/1997                     | Khanna et al.                                   |   |
|                    | TR-737                | US- 5,700,816   | 12/23/1997                     | Isakson et al.                                  |   |
|                    | TR-738                | US- 5,753,887   | 05/19/1998                     | Mjalli et al.                                   |   |
|                    | TR-739                | US- 5,840,721   | 11/24/1998                     | Mjalli et al.                                   |   |
|                    | TR-740                | US- 5,958,957   | 09/28/1999                     | Andersen et al.                                 |   |
|                    | TR-741                | US- 5,972,986   | 10/26/1999                     | Seibert et al.                                  |   |
|                    | TR-742                | US- 5,990,148   | 11/23/1999                     | Isakson et al.                                  |   |
|                    | TR-743                | US- 6,136,839   | 10/24/2000                     | Isakson et al.                                  |   |
|                    | TR-744                | US- 6,159,944   | 12/12/2000                     | McDonald et al.                                 |   |
|                    | TR-745                | US- 6,285,426   | 07/24/2001                     | Alanine et al.                                  |   |
|                    | TR-746                | US- 6,358,634   | 03/19/2002                     | Igarashi et al.                                 |   |
|                    | TR-747                | US- 6,589,953   | 07/08/2003                     | Perez et al.                                    |   |
|                    | TR-748                | US- 6,627,647   | 09/30/2003                     | Betageri  |   |
|                    | TR-749                | US- 2003-0220372  | 11/27/2003                     | Hirano et al.                                   |   |
|                    | TR-750                | US- 2004-0167187  | 08/26/2004                     | Saunders et al.                                 |   |
|                    | TR-751                | US- 2004-0176395  | 09/09/2004                     | Flynn et al.                                    |   |
|                    | TR-752                | US- 2004-0180806  | 09/16/2004                     | Flynn et al.                                    |   |
| LLS                | TR-753                | US- 2005-0272778  | 12/08/2005                     | Combs et al.                                    |   |

## FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Foreign Patent Document<br>Country Code <sup>2</sup> - Number <sup>3</sup> - Kind Code <sup>4</sup> (if known) | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant<br>Passages or Relevant<br>Figures Appear | T <sup>5</sup> |
|--------------------|-----------------------|--|--------------------------------|---|---|----------------|
| LLS                | TR-414                | JP 09040651  | 02/10/1997                     | Yasushi et al.                                  |   | ✓              |
|                    | TR-417                | JP 2003313170  | 11/06/2003                     | Takahashi et al.                                |   | ✓              |
|                    | TR-418                | JP 2003313172  | 11/06/2003                     | Takahashi et al.                                |   | ✓              |
|                    | TR-754                | JP 05261293  | 10/12/1993                     | Benazzi et al.                                  |   | ✓              |
|                    | TR-755                | JP 63276054  | 11/14/1988                     | Shigeo et al.                                   |   |                |
|                    | TR-756                | WO 199417059   | 08/04/1994                     | Miyazawa et al.                                 |   |                |
|                    | TR-757                | WO 199641626   | 12/27/1996                     | Isakson et al.                                  |   |                |
|                    | TR-758                | WO 199816227   | 4/23/1998                      | Seibert et al.                                  |   |                |
|                    | TR-759                | WO 199851673   | 11/19/1998                     | Earnshaw et al.                                 |   |                |
|                    | TR-760                | WO 200027826   | 05/18/2000                     | Lehmann-Lintz et al.                            |   |                |
|                    | TR-761                | WO 2004069394  | 08/19/2004                     | Sames et al.                                    |   |                |
|                    | TR-762                | WO 2004094395  | 11/04/2004                     | Chakravarty et al.                              |   |                |
| LLS                | TR-764                | CA 2158529   | 03/27/1996                     | Marten et al.                                   |   |                |

Examiner  
Signature

/Laura L. Stockton/

Date  
Considered

01/18/2007

\*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the right of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to be (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. The collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete the form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1430, Alexandria, VA 22313-1430.

If you need assistance in completing the form, call 1-800-PTO-4199 and select option 2.

EV 841058245 US

PTO/SB/08b(08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 3

**Complete if Known**

|                        |                   |
|------------------------|-------------------|
| Application Number     | 10/777,488        |
| Filing Date            | February 12, 2004 |
| First Named Inventor   | Adnan M.M. Mjalli |
| Art Unit               | 1626              |
| Examiner Name          | Laura Stockton    |
| Attorney Docket Number | TTP 2002-08       |

| NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials *             | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.                             | T <sup>2</sup> |
| LLS                             | TR-47                 | TAYLOR SD, "Inhibitors of protein tyrosine phosphatase 1B (PTP1B)." Current Topics in Medicinal Chemistry, 3:759-782 (2003)   |                |
|                                 | TR-48                 | TAO J, "Insulin stimulates tyrosine phosphorylation and inactivation of protein-tyrosine phosphatase 1B in vivo." The Journal of Biological Chemistry, 276:29520-29525 (2001)   |                |
|                                 | TR-49                 | DADKE S, "Interaction of protein tyrosine phosphatase (PTP) 1B with its substrates is influenced by two distinct binding domains." Biochemical Journal, 364:377-383 (2002)  |                |
|                                 | TR-51                 | BLANCHETOT C, "Intra- and intermolecular interactions between intracellular domains of receptor protein-tyrosine phosphatases." The Journal of Biological Chemistry, 277:47263-47269 (2002)   |                |
|                                 | TR-52                 | HAASE H, "Intracellular zinc fluctuations modulate protein tyrosine phosphatase activity in insulin/insulin-like growth factor-1 signaling." Experimental Cell Research, 291:289-298 (2003)   |                |
|                                 | TR-53                 | LILJEBRIS C, "Investigation of potential bioisosteric replacements for the carboxyl groups of peptidomimetic inhibitors of protein tyrosine phosphatase 1B: identification of a tetrazole-containing inhibitor with cellular activity." Journal of Medicinal Chemistry, 45:1785-1798 (2002) |                |
|                                 | TR-54                 | FRIMURER TM, "Ligand-induced conformational changes: improved predictions of ligand binding conformations and affinities." Biophysical Journal, 84:2273-2281 (2003)   |                |
|                                 | TR-55                 | TJERNBERG A, "Mechanism of action of pyridazine analogues on protein tyrosine phosphatase 1B (PTP1B)" Bioorganic & Medicinal Chemistry Letters, 14:891-895 (2004)   |                |
|                                 | TR-56                 | LARSEN SD, "Modification of the N-terminus of peptidomimetic protein tyrosine phosphatase 1B (PTP1B) inhibitors: identification of analogues with cellular activity." Bioorganic & Medicinal Chemistry Letters, 13:971-975 (2003)   |                |
|                                 | TR-57                 | SALMEEN A, "Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B." Molecular Cell, 6:1401-1412 (2000)   |                |
|                                 | TR-58                 | UMEZAWA K, "Molecular design and biological activities of protein-tyrosine phosphatase inhibitors." Pharmacology & Therapeutics, 99:15-24 (2003)  |                |
|                                 | TR-346                | COCCO et al., "L-Acylaminoimidazoles Synthesis and Antimicrobial Activity", Farmaco, vol. 47, no. 2, pages 229-238, (1992)  |                |
|                                 | TR-347                | International Search Report for PCT application PCT/US2005/004590 mailed September 8, 2005.   |                |
|                                 | TR-348                | LAUFER et al., "Imidazole Inhibitors of Cytokine Release: Probing Substituents in the 2 Position", vol. 45, pages 4695-4705, (2002)   |                |
|                                 | TR-349                | LIPSHUTZ et al., "Metalation Studies of Trisubstituted Oxazoles", Journal of Organic Chemistry, vol. 46, pages 1410-1413, (1981)  |                |
| ✓                               | TR-350-A              | MEANWELL et al., "Nonprostanoid prostacyclin mimetics. 2. 4, 5-Diphenyloxazole derivatives", Journal of Medicinal Chemistry, vol. 35, no. 19, pages 3483-3497, (1992)   |                |
| LLS                             | TR-763                | Combs et al., "Structure-based design and discovery of protein tyrosine phosphatase inhibitors incorporating novel isothiazolidinone heterocyclic phosphotyrosine mimetics" Journal of Medicinal Chemistry, Vol. 48, pp. 6544-6548 (2005).  |                |

|                    |                     |                 |            |
|--------------------|---------------------|-----------------|------------|
| Examiner Signature | /Laura L. Stockton/ | Date Considered | 01/18/2007 |
|--------------------|---------------------|-----------------|------------|

\*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language translation is attached.  
 This collection of information is required by 37 CFR 1.06. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-0199 and select option 2.

**EV 841058245 US**

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form-1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(Use as many sheets as necessary)**

|       |   |    |   |
|-------|---|----|---|
| Sheet | 3 | of | 3 |
|-------|---|----|---|

**Complete If Known**

|                               |                   |
|-------------------------------|-------------------|
| <b>Application Number</b>     | 10/777,488        |
| <b>Filing Date</b>            | February 12, 2004 |
| <b>First Named Inventor</b>   | Adnan M.M. Mjalli |
| <b>Art Unit</b>               | 1626              |
| <b>Examiner Name</b>          | Laura Stockton    |
| <b>Attorney Docket Number</b> | TTP 2002-08       |

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

| FOREIGN PATENT DOCUMENTS |                       |  |                                |   |  |                |
|--------------------------|-----------------------|--|--------------------------------|---|--|----------------|
| Examiner<br>Initials*    | Cite No. <sup>1</sup> | Foreign Patent Document  | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited<br>Document | Pages, Columns,<br>Lines, Where Relevant<br>Passages or Relevant<br>Figures Appear | T <sup>6</sup> |
|                          |                       | Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if<br>known) |                                |   |  |                |
| LLS                      | TR-334                | EP 1 227 084   | 07/31/2002                     | Leger et al.  |  |                |
|                          | TR-335                | EP 1 253 142   | 10/30/2002                     | Takemoto et al.                                       |  |                |
|                          | TR-336                | EP 1 452 530   | 09/01/2004                     | Inaba et al.  |  |                |
|                          | TR-337                | JP 2002-114768   | 04/16/2002                     | Takeshi et al.  |  | ✓              |
|                          | TR-338                | JP 2003-231679   | 08/19/2003                     | Atsunori et al.                                       |  | ✓              |
|                          | TR-339                | WO 1994-008982   | 04/28/1994                     | Kumita et al.   |  |                |
|                          | TR-340                | WO 2000-071120   | 11/30/2000                     | Heerding et al.                                       |  |                |
|                          | TR-341                | WO 2003-075921   | 09/18/2003                     | Mjalli et al.   |  |                |
|                          | TR-342                | WO 2003-093263   | 11/13/2003                     | Maynard et al.  |  |                |
|                          | TR-343                | WO 2004-013141   | 02/12/2004                     | Luke et al.   |  |                |
|                          | TR-344                | WO 2004-063169   | 07/29/2004                     | Urano et al.  |  |                |
|                          | TR-345                | WO 2004-089918   | 10/21/2004                     | Ikemoto et al.  |  |                |
| LLS                      | TR-766                | EP 1 553 091   | 07/13/2005                     | Ikemoto et al.  |  |                |

**Examiner  
Signature**

/Laura L. Stockton/

Date Considered

01/18/2007

**EXAMINER:** Initial a reference considered, whether or not citation is in conformance with MPEP 809. Draw time through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup>  
 \* Applicant's unique citation designation number (optional): See Kinds/Classes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP P01.04. \* Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).  
 \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \* Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.67 and 1.68. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. As the information is required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

**If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |                          |                   |
|--|---|--------------------------|-------------------|
| Substitute for form 1449A/PTO                            |   | <b>Complete If Known</b> |                   |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b> |   | Application Number       | 10/777.488        |
|  |   | Filing Date              | 02/12/04          |
|  |   | First Named Inventor     | Adnan M.M. Mjalli |
|  |   | Art Unit                 | 1614              |
|  |   | Examiner Name            | Unknown           |
| (Use as many sheets as necessary)                        |   | Attorney Docket Number   | TTP 2002-08       |
| Sheet  | 1 | of                       | 9                 |

[illegible]

| FOREIGN PATENT DOCUMENTS |                       |  |                                |   |  |                |
|--------------------------|-----------------------|--|--------------------------------|---|--|----------------|
| Examiner Initials*       | Cite No. <sup>1</sup> | Foreign Patent Document  | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited<br>Document | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear | T <sup>6</sup> |
|                          |                       | Country Code <sup>2</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if<br>known) |                                |   |  |                |
| LLS                      | TR-232                | WO 97/39748  | 10/30/97                       | Andersen et al.                                       |  |                |
| ↓                        | TR-233                | WO 98/27065  | 06/25/98                       | Mjalli et al.   |  |                |
|                          | TR-230                | WO 99/46244  | 09/16/99                       | Jeppesen et al.                                       |  |                |
|                          | TR-227                | WO 02/32897  | 04/25/02                       | Day et al.  |  |                |
|                          | TR-143                | WO 02/04412  | 01/17/02                       | Burgess et al.  |  |                |
|                          | TR-144                | WO 02/04459  | 01/17/02                       | Anderson et al.                                       |  |                |
| ↓                        | TR-145                | WO 03/020688   | 03/13/03                       | Liu et al.  |  |                |
| LLS                      | TR-146                | WO 03/033496   | 04/24/03                       | Mjalli et al.   |  |                |

|                       |                     |                    |            |
|-----------------------|---------------------|--------------------|------------|
| Examiner<br>Signature | /Laura L. Stockton/ | Date<br>Considered | 01/18/2007 |
|-----------------------|---------------------|--------------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |    |    |                          |                   |
|--|---|----|----|--------------------------|-------------------|
| Substitute for form 1448A/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use as many sheets as necessary) |   |    |    | <b>Complete If Known</b> |                   |
|  |   |    |    | Application Number       | 10/777,488        |
|  |   |    |    | Filing Date              | 02/12/04          |
|  |   |    |    | First Named Inventor     | Adnan M.M. Mjalli |
|  |   |    |    | Art Unit                 | 1614              |
|  |   |    |    | Examiner Name            | Unkown            |
|  |   |    |    | Attorney Docket Number   | TTP 2002-08       |
| Sheet  | 2 | of | 19 |                          |                   |

[illegible]

| FOREIGN PATENT DOCUMENTS   |                       |  |                                   |  |  |                |
|--|-----------------------|--|-----------------------------------|--|--|----------------|
| Examiner<br>Initials*  | Cite No. <sup>1</sup> | Foreign Patent Document  | Publication<br>Date<br>MM-DD-YYYY | Name of Patentee or Applicant of<br>Cited Document | Pages,<br>Columns, Lines,<br>Where Relevant<br>Passages or<br>Relevant<br>Figures Appear | T <sup>6</sup> |
|  |                       | Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if<br>known) |                                   |  |  |                |
| <div style="text-align: center;">  </div> | TR-147                | WO 03/041729   | 05/22/03                          | Zhang et al.                                       |  |                |
|  | TR-148                | WO 03/048140   | 06/12/03                          | Inaba et al.                                       |  |                |
|  | TR-149                | WO 03/064376   | 08/07/03                          | Swinnen et al.                                     |  |                |
|  | TR-150                | WO 03/072537   | 09/04/03                          | Szezepankiewicz et al.                             |  |                |
|  | TR-151                | WO 03/073987   | 09/12/03                          | Barr et al.  |  |                |
|  | TR-152                | WO 03/082841   | 10/09/03                          | Coppola et al.                                     |  |                |
|  | TR-153                | WO 03/092679   | 11/13/03                          | Groneberg et al.                                   |  |                |
|  | TR-154                | WO 03/093498   | 11/13/03                          | Pei et al.   |  |                |
| LLS  | TR-156                | WO 04/020466   | 03/11/04                          | Hooft et al.                                       |  |                |

|                       |                     |                    |            |
|-----------------------|---------------------|--------------------|------------|
| Examiner<br>Signature | /Laura L. Stockton/ | Date<br>Considered | 01/18/2007 |
|-----------------------|---------------------|--------------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

***If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.***

Substitute for form 1448A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

3

of

19

**Complete If Known**

|                        |                   |
|------------------------|-------------------|
| Application Number     | 10/777,488        |
| Filing Date            | 02/12/04          |
| First Named Inventor   | Adnan M.M. Mjalli |
| Art Unit               | 1614              |
| Examiner Name          | Unknown           |
| Attorney Docket Number | TTP 2002-08       |

**U.S. PATENT DOCUMENTS**

| Examiner<br>Initials * | Cite<br>No. <sup>1</sup> | Document Number                            | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant of<br>Cited Document | Pages, Columns, Lines, Where Relevant<br>Passages or Relevant<br>Figures Appear |
|------------------------|--------------------------|--|--------------------------------|--|---|
|                        |                          | Number - Kind Code <sup>2</sup> (if known) |                                |  |   |
|                        |                          | US-  |                                |  |   |
|                        |                          | US-  |                                |  |   |
|                        |                          | US-  |                                |  |   |
|                        |                          | US-  |                                |  |   |
|                        |                          | US-  |                                |  |   |
|                        |                          | US-  |                                |  |   |
|                        |                          | US-  |                                |  |   |
|                        |                          | US-  |                                |  |   |
|                        |                          | US-  |                                |  |   |
|                        |                          | US-  |                                |  |   |
|                        |                          | US-  |                                |  |   |
|                        |                          | US-  |                                |  |   |
|                        |                          | US-  |                                |  |   |
|                        |                          | US-  |                                |  |   |
|                        |                          | US-  |                                |  |   |
|                        |                          | US-  |                                |  |   |
|                        |                          | US-  |                                |  |   |
|                        |                          | US-  |                                |  |   |
|                        |                          | US-  |                                |  |   |
|                        |                          | US-  |                                |  |   |
|                        |                          | US-  |                                |  |   |

**FOREIGN PATENT DOCUMENTS**

| Examiner<br>Initials * | Cite No. <sup>1</sup> | Foreign Patent Document  | Publication<br>Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited<br>Document | Pages, Columns,<br>Lines, Where<br>Relevant Passages or<br>Relevant Figures<br>Appear | T <sup>6</sup> |
|------------------------|-----------------------|--|-----------------------------------|---|---|----------------|
|                        |                       | Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if<br>known) |                                   |   |   |                |
| LLS                    | TR-157                | WO 04/041799   | 05/21/04                          | Birch et al.  |   |                |
|                        | TR-158                | WO 04/050646   | 06/17/04                          | Kenny et al.  |   |                |
|                        | TR-159                | WO 04/071447   | 08/26/04                          | Mjalli et al.   |   |                |
|                        | TR-160                | WO 04/071448   | 08/26/04                          | Mjalli et al.   |   |                |
|                        | TR-161                | WO 04/074238   | 09/02/04                          | Gray et al.   |   |                |
| LLS                    | TR-162                | WO 04/074256   | 09/02/04                          | Klopfenstein et al.                                   |   |                |
|                        |                       |  |                                   |   |   |                |
|                        |                       |  |                                   |   |   |                |
|                        |                       |  |                                   |   |   |                |
|                        |                       |  |                                   |   |   |                |
|                        |                       |  |                                   |   |   |                |
|                        |                       |  |                                   |   |   |                |
|                        |                       |  |                                   |   |   |                |
|                        |                       |  |                                   |   |   |                |
|                        |                       |  |                                   |   |   |                |
|                        |                       |  |                                   |   |   |                |
|                        |                       |  |                                   |   |   |                |
|                        |                       |  |                                   |   |   |                |
|                        |                       |  |                                   |   |   |                |
|                        |                       |  |                                   |   |   |                |
|                        |                       |  |                                   |   |   |                |

Examiner  
Signature

/Laura L. Stockton/

Date  
Considered

01/18/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9189 and select option 2.

NOV 30 2004  
U.S. PATENT & TRADEMARK OFFICE

PTO/SB/08a (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 19

### Complete if Known

|                        |                   |
|------------------------|-------------------|
| Application Number     | 10/777,488        |
| Filing Date            | 02/12/04          |
| First Named Inventor   | Adnan M.M. Mjalli |
| Art Unit               | 1614              |
| Examiner Name          | Unknown           |
| Attorney Docket Number | TTP 2002-08       |

### U.S. PATENT DOCUMENTS

| Examiner<br>Initials * | Cite No. <sup>1</sup> | Document Number                               |  | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant of<br>Cited Document | Pages, Columns, Lines, Where Relevant<br>Passages or Relevant<br>Figures Appear |
|------------------------|-----------------------|---|--|--------------------------------|--|---|
|                        |                       | Number - Kind Code <sup>2</sup> (if<br>known) |  |                                |  |   |
| LLS                    | TR-131                | US- 5,972,978                                 |  | 10/28/1999                     | Andersen et al.                                    |   |
|                        | TR-164                | US- 6,169,087                                 |  | 01/02/2001                     | Andersen et al.                                    |   |
|                        | TR-165                | US- 6,174,874                                 |  | 01/16/2001                     | Wang et al.  |   |
|                        | TR-166                | US- 6,214,584                                 |  | 04/10/2001                     | Rodan et al.                                       |   |
|                        | TR-167                | US- 6,238,902                                 |  | 05/29/2001                     | Cheng et al.                                       |   |
|                        | TR-169                | US- 6,388,076                                 |  | 05/14/2002                     | Mjalli et al.                                      |   |
|                        | TR-170                | US- 6,365,592                                 |  | 04/02/2002                     | Leblanc et al.                                     |   |
|                        | TR-171                | US- 6,410,556                                 |  | 08/25/2002                     | Andersen et al.                                    |   |
|                        | TR-172                | US- 6,448,428                                 |  | 09/10/2002                     | Leblanc et al.                                     |   |
|                        | TR-173                | US- 6,465,444                                 |  | 10/15/2002                     | Bayty et al.                                       |   |
|                        | TR-174                | US- 6,472,545                                 |  | 10/29/2002                     | Liu et al.   |   |
|                        | TR-175                | US- 6,486,141                                 |  | 11/26/2002                     | Lau et al.   |   |
|                        | TR-176                | US- 6,486,142                                 |  | 11/26/2002                     | Leblanc et al.                                     |   |
|                        | TR-177                | US- 6,498,151                                 |  | 12/24/2002                     | Li et al.  |   |
|                        | TR-178                | US- 6,534,056                                 |  | 03/18/2003                     | Tromblay et al.                                    |   |
|                        | TR-179                | US- 6,583,126                                 |  | 06/24/2003                     | Leblanc et al.                                     |   |
|                        | TR-180                | US- 6,566,467                                 |  | 07/01/2003                     | Burgess et al.                                     |   |
| LLS                    | TR-181                | US- 6,596,772                                 |  | 07/22/2003                     | Huang et al.                                       |   |

### FOREIGN PATENT DOCUMENTS

| Examiner<br>Initials * | Cite<br>No. <sup>1</sup> | Foreign Patent Document   |  | Publication<br>Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited<br>Document | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear | T <sup>3</sup> |
|------------------------|--------------------------|---|--|-----------------------------------|---|--|----------------|
|                        |                          | Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known) |  |                                   |   |  |                |
|                        |                          |   |  |                                   |   |  |                |
|                        |                          |   |  |                                   |   |  |                |
|                        |                          |   |  |                                   |   |  |                |
|                        |                          |   |  |                                   |   |  |                |
|                        |                          |   |  |                                   |   |  |                |
|                        |                          |   |  |                                   |   |  |                |
|                        |                          |   |  |                                   |   |  |                |
|                        |                          |   |  |                                   |   |  |                |
|                        |                          |   |  |                                   |   |  |                |
|                        |                          |   |  |                                   |   |  |                |
|                        |                          |   |  |                                   |   |  |                |
|                        |                          |   |  |                                   |   |  |                |
|                        |                          |   |  |                                   |   |  |                |
|                        |                          |   |  |                                   |   |  |                |
|                        |                          |   |  |                                   |   |  |                |
|                        |                          |   |  |                                   |   |  |                |
|                        |                          |   |  |                                   |   |  |                |
|                        |                          |   |  |                                   |   |  |                |
|                        |                          |   |  |                                   |   |  |                |

Examiner  
Signature

/Laura L. Stockton/

Date  
Considered

01/18/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US



Substitute for form 1448A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 5 of 19**Complete If Known**

|                        |                   |
|------------------------|-------------------|
| Application Number     | 10/777,488        |
| Filing Date            | 02/12/04          |
| First Named Inventor   | Adnan M.M. Mjalli |
| Art Unit               | 1614              |
| Examiner Name          | Unknown           |
| Attorney Docket Number | TTP 2002-08       |

**U.S. PATENT DOCUMENTS**

| Examiner<br>Initials *                                  | Cite No. <sup>1</sup> | Document Number                               | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant of<br>Cited Document | Pages, Columns, Lines, Where Relevant<br>Passages or Relevant<br>Figures Appear |
|---|-----------------------|---|--------------------------------|--|---|
|   |                       | Number - Kind Code <sup>2</sup> (if<br>known) |                                |  |   |
| LLS<br>↓<br>↓<br>↓<br>↓<br>↓<br>↓<br>↓<br>↓<br>↓<br>LLS | TR-182                | US- 6,605,753                                 | 08/12/2003                     | Kennedy et al.                                     |   |
|   | TR-183                | US- 6,613,903                                 | 09/02/2003                     | Andersen et al.                                    |   |
|   | TR-184                | US- 6,627,767                                 | 09/30/2003                     | Liu et al.   |   |
|   | TR-185                | US- 6,699,896                                 | 03/02/2004                     | Malamas et al.                                     |   |
|   | TR-186                | US- 6,765,021                                 | 07/20/2004                     | Butera et al.                                      |   |
|   | TR-187                | US- 6,770,466                                 | 08/03/2004                     | Shi et al.   |   |
|   | TR-188                | US- 6,777,433                                 | 08/17/2004                     | Leblanc et al.                                     |   |
|   | TR-189                | US- 6,784,205                                 | 08/31/2004                     | Barr et al.  |   |
|   |                       |   | US-                            |  |   |
|   |                       | US-   |                                |  |   |
|   |                       | US-   |                                |  |   |
|   |                       | US-   |                                |  |   |
|   |                       | US-   |                                |  |   |
|   |                       | US-   |                                |  |   |
|   |                       | US-   |                                |  |   |
|   |                       | US-   |                                |  |   |
|   |                       | US-   |                                |  |   |
|   |                       | US-   |                                |  |   |
|   |                       | US-   |                                |  |   |
|   |                       | US-   |                                |  |   |
|   |                       | US-   |                                |  |   |
|   |                       | US-   |                                |  |   |
|   |                       | US-   |                                |  |   |

**FOREIGN PATENT DOCUMENTS**

| Examiner<br>Initials* | Cite<br>No. <sup>1</sup> | Foreign Patent Document   | Publication<br>Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited<br>Document | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear | T <sup>6</sup> |
|-----------------------|--------------------------|---|-----------------------------------|---|--|----------------|
|                       |                          | Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known) |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   |  |                |
|                       |                          |   |                                   |   | </   |                |

Examiner  
Signature

/Laura L. Stockton/

Date  
Considered

01/18/2007


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US

EV 507590141 US



PTO/SB/08a (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

7

of

19

**Complete If Known**

|                        |                   |
|------------------------|-------------------|
| Application Number     | 10/777,488        |
| Filing Date            | 02/12/04          |
| First Named Inventor   | Adnan M.M. Mjalli |
| Art Unit               | 1614              |
| Examiner Name          | Unknown           |
| Attorney Docket Number | TTP 2002-08       |

**U.S. PATENT DOCUMENTS**

| Examiner<br>Initials * | Cite No. <sup>1</sup> | Document Number                               | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant of<br>Cited Document | Pages, Columns, Lines, Where Relevant<br>Passages or Relevant<br>Figures Appear |
|------------------------|-----------------------|---|--------------------------------|--|---|
|                        |                       | Number - Kind Code <sup>2</sup> (if<br>known) |                                |  |   |
| LLS<br>↓<br>V          | TR-211                | US- 20040009946                               | 01/15/2004                     | Lewis et al.                                       |   |
|                        | TR-212                | US- 20040009956                               | 01/15/2004                     | Pei et al.   |   |
|                        | TR-213                | US- 20040014778                               | 01/22/2004                     | Mjalli et al.                                      |   |
|                        | TR-214                | US- 20040023974                               | 02/05/2004                     | Coppola et al.                                     |   |
|                        | TR-215                | US- 20040121353                               | 08/24/2004                     | Lewis et al.                                       |   |
|                        | TR-216                | US- 20040127570                               | 07/01/2004                     | Mayer et al.                                       |   |
|                        | TR-217                | US- 20040138218                               | 07/15/2004                     | Pallen et al.                                      |   |
|                        | TR-218                | US- 20040147596                               | 07/29/2004                     | Barr et al.  |   |
|                        | TR-219                | US- 20040147755                               | 07/29/2004                     | Malamas et al.                                     |   |
|                        | TR-220                | US- 20040167188                               | 08/26/2004                     | Zhili et al.                                       |   |
|                        | TR-221                | US- 20040176330                               | 09/09/2004                     | Dufresne et al.                                    |   |
|                        |                       |   |                                |  |   |
|                        |                       |   |                                |  |   |
|                        |                       |   |                                |  |   |
|                        |                       |   |                                |  |   |
|                        |                       |   |                                |  |   |
|                        |                       |   |                                |  |   |
|                        |                       |   |                                |  |   |

**FOREIGN PATENT DOCUMENTS**

| Examiner<br>Initials * | Cite<br>No. <sup>1</sup> | Foreign Patent Document   | Publication<br>Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited<br>Document | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear | T <sup>o</sup> |
|------------------------|--------------------------|---|-----------------------------------|---|--|----------------|
|                        |                          | Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known) |                                   |   |  |                |
|                        |                          |   |                                   |   |  |                |
|                        |                          |   |                                   |   |  |                |
|                        |                          |   |                                   |   |  |                |
|                        |                          |   |                                   |   |  |                |
|                        |                          |   |                                   |   |  |                |
|                        |                          |   |                                   |   |  |                |
|                        |                          |   |                                   |   |  |                |
|                        |                          |   |                                   |   |  |                |
|                        |                          |   |                                   |   |  |                |
|                        |                          |   |                                   |   |  |                |
|                        |                          |   |                                   |   |  |                |
|                        |                          |   |                                   |   |  |                |
|                        |                          |   |                                   |   |  |                |
|                        |                          |   |                                   |   |  |                |
|                        |                          |   |                                   |   |  |                |

Examiner  
Signature

/Laura L. Stockton/

Date  
Considered

01/18/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

9

of

9

**Complete If Known**

Application Number 10/777,488

Filing Date 02/12/04

First Named Inventor Adnan M.M. Mjalli

Art Unit 1614

Examiner Name Unknown

Attorney Docket Number TTP 2002-08

**NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials * | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|---------------------|-----------------------|---|----------------|
| LLS                 | TR-1                  | ANDERSEN HS, "2-(oxalylamino)-benzoic acid is a general, competitive inhibitor of protein-tyrosine phosphatases." The Journal of Biological Chemistry, 275:7101-7108 (2000)   |                |
|                     | TR-2                  | MURTHY VS, "3D-QSAR CoMFA and CoMSIA on Protein Tyrosine Phosphatase 1B Inhibitors" Bioorganic & Medicinal Chemistry, 10:2267-2282 (2002)   |                |
|                     | TR-3                  | MOK A, "A single nucleotide polymorphism in protein tyrosine phosphatase PTP-1B is associated with protection from diabetes or impaired glucose Tolerance in Oji-Cree" The Journal of Clinical Endocrinology & Metabolism, 87(2): 724-727 (2002)                |                |
|                     | TR-4                  | SHEN K, "Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure." The Journal of Biological Chemistry, 276:47311-47319 (2001)  |                |
|                     | TR-5                  | COVIC L, "Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides." Proceedings of the National Academy of Sciences, 99:643-648 (2002)  |                |
|                     | TR-6                  | LIU DG, "Acylsulfonamide-containing PTP1B inhibitors designed to mimic an enzyme-bound water of hydration." Bioorganic & Medicinal Chemistry Letters, 13:3005-3007 (2003)   |                |
|                     | TR-7                  | WIESMANN C, "Allosteric inhibition of protein tyrosine phosphatase 1B" Nature Structural & Molecular Biology, 11:730-737 (2004)   |                |
|                     | TR-8                  | LI X, "Alpha, alpha-difluoro-beta-ketophosphonates as potent inhibitors of protein tyrosine phosphatase 1B." Bioorganic & Medicinal Chemistry Letters, 14:4301-4306 (2004)  |                |
|                     | TR-9                  | ARABACI G, "alpha-bromoacetophenone derivatives as neutral protein tyrosine phosphatase inhibitors: structure-Activity relationship." Bioorganic & Medicinal Chemistry Letters, 12:3047-3050 (2002)   |                |
| ✓                   | TR-10                 | CHO KJ, "Alpha-lipoic acid decreases thiol reactivity of the Insulin receptor and protein tyrosine phosphatase 1B in 3T3-L1 adipocytes." Biochemical Pharmacology, 66:849-858 (2003)  |                |
| LLS                 | TR-11                 | AHMAD F, "Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in Insulin-resistant human obesity and diabetes." Journal of Clinical Investigation, 100:449-458 (1997)   |                |

|                    |                     |                 |            |
|--------------------|---------------------|-----------------|------------|
| Examiner Signature | /Laura L. Stockton/ | Date Considered | 01/18/2007 |
|--------------------|---------------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 10 of 19**Complete if Known**

|                        |                   |
|------------------------|-------------------|
| Application Number     | 10/777,488        |
| Filing Date            | 02/12/04          |
| First Named Inventor   | Adnan M.M. Mjalli |
| Art Unit               | 1614              |
| Examiner Name          | Unknown           |
| Attorney Docket Number | TTP 2002-08       |

**NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials * | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.   | T <sup>2</sup> |
|---------------------|-----------------------|---|----------------|
| LLS                 | TR-12                 | WANG WQ, "An overview of the protein tyrosine phosphatase superfamily." Current Topics in Medicinal Chemistry, 3:739-748 (2003)   |                |
|                     | TR-13                 | GUM RJ, "Antisense Protein Tyrosine Phosphatase 1B Reverses Activation of p38 Mitogen-Activated Protein Kinase in Liver of ob/ob Mice." Molecular Endocrinology, 17:1131-1143 (2003)  |                |
|                     | TR-14                 | VETTER SW, "Assessment of protein-tyrosine phosphatase 1B substrate specificity using "inverse alanine scanning"." The Journal of Biological Chemistry, 275:2265-2268 (2000)  |                |
|                     | TR-15                 | PATANI G, "Bioisosterism: A Rational Approach in Drug Design." Chemical Review, 99, 3147-3176 (1998)  |                |
|                     | TR-16                 | LEE K, "CD45 protein-tyrosine phosphatase inhibitor development." Current Topics in Medicinal Chemistry, 3:797-807 (2003)   |                |
|                     | TR-17                 | IRIE-SASAKI J, "CD45 regulated signaling pathways." Current Topics in Medicinal Chemistry, 3:783-996 (2003)   |                |
|                     | TR-18                 | CHU W, "Cell-free Synthesis of Preparative Amounts of Enzymatically Active Human PTP1B" Biochemica, 2:28-29 (2001)  |                |
|                     | TR-19                 | XIE L, "Cellular effects of small molecule PTP1B inhibitors on insulin signaling." Biochemistry, 42:12792-12804 (2003)  |                |
|                     | TR-20                 | TAYLOR WP, "Charged with meaning: the structure and mechanism of phosphoprotein phosphatases." Chemistry & Biology, 2:713-718 (1995)  |                |
|                     | TR-21                 | PATANKAR SJ, "Classification of Inhibitors of Protein Tyrosine Phosphatase 1B Using Molecular Structure Based Descriptors " Journal of Chemical Information and Computer Sciences, 43:885-899 (2003)  |                |
|                     | TR-22                 | SUN JP, "Crystal structure of PTP1B complexed with a potent and selective bidentate inhibitor." The Journal of Biological Chemistry, 278:12408-12414 (2003)   |                |
| ↓                   | TR-23                 | DATABASE CAPLUS "Online! Chemical Abstracts Service, Columbus, Ohio, US; HOSHINO, KAZUKI et al: "Anti-infective agents and drug efflux pump inhibitors containing heteroaromatic compounds and" retrieved from STN Database accession no. 2002: 849289 RN 3347904-05-9, RN 337903-86-5, abstract & JP 2002 322054, Japan; 8 November 2002 |                |
| LLS                 | TR-24                 | YAN Z, "Design and synthesis of phosphotyrosine mimetics." Bioorganic & Medicinal Chemistry Letters, 13:2083-2085 (2003)  |                |

Examiner  
Signature

/Laura L. Stockton/

Date  
Considered


01/18/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US



PTO/SB/08b(08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

11

of

18

### Complete if Known

Application Number 10/777,488

Filing Date 02/12/04

First Named Inventor Adnan M.M. Mjalli

Art Unit 1614

Examiner Name Unknown

Attorney Docket Number TTP 2002-08

### NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|---------------------|-----------------------|---|----------------|
| LLS                 | TR-25                 | ANDERSEN HS, "Discovery and SAR of a novel selective and orally bioavailable nonpeptide classical competitive inhibitor class of protein-tyrosine phosphatase 1B." Journal of Medicinal Chemistry, 45:4443-4459 (2002)  |                |
|                     | TR-26                 | PEI Z, "Discovery and SAR of novel, potent and selective protein tyrosine phosphatase 1B inhibitors." Bioorganic & Medicinal Chemistry Letters, 13:3129-3132 (2003)   |                |
|                     | TR-27                 | LIU G, "Discovery and structure-activity relationship of oxalylarylamino benzoic acids as inhibitors of protein tyrosine phosphatase 1B." Journal of Medicinal Chemistry, 46:2093-2103 (2003)   |                |
|                     | TR-28                 | ERLANSON DA, "Discovery of a New Phosphotyrosine Mimetic for PTP1B Using Breakaway Tethering" Journal of the American Chemical Society, 125:5602-5603 (2003)  |                |
|                     | TR-29                 | HYAE GYEONG CHEON, "Discovery of a novel protein tyrosine phosphatase-1B inhibitor, KR61639: potential development as an antihyperglycemic agent" European Journal of Pharmacology, 485:333-339 (2004)  |                |
|                     | TR-30                 | OCKEY DA, "Discovery of novel PTP1b inhibitors " Bioorganic & Medicinal Chemistry Letters, 14:389-391 (2004)  |                |
|                     | TR-31                 | CHEN YT, "Divalent and trivalent alpha-ketocarboxylic acids as inhibitors of protein tyrosine phosphatases." Journal of Medicinal Chemistry, 45:3946-3952 (2002)  |                |
|                     | TR-32                 | BOUTE N, "Dynamics of the interaction between the insulin receptor and protein tyrosine-phosphatase 1B in living cells." EMBO Reports, 4:313-319 (2003)   |                |
|                     | TR-33                 | PETRONE A, "Emerging issues in receptor protein tyrosine phosphatase function: lifting fog or simply shifting?" Journal of Cell Science, 113:2345-2354 (2000)   |                |
|                     | TR-34                 | PETERS GH, "Enzyme kinetic characterization of protein tyrosine phosphatases" Biochimie, 85:527-534 (2003)  |                |
| LLS                 | TR-35                 | SHRESTHA S, "Evans Blue and other dyes as protein tyrosine phosphatase inhibitors." Bioorganic & Medicinal Chemistry Letters, 14:1923-1926 (2004)   |                |

Examiner  
Signature

/Laura L. Stockton/

Date  
Considered

01/18/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US



|  |    |                               |                   |
|--|----|-------------------------------|-------------------|
| Institute for form 1449B/PTO                             |    | <b>Complete if Known</b>      |                   |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b> |    | <b>Application Number</b>     | 10/777,488        |
|  |    | <b>Filing Date</b>            | 02/12/04          |
|  |    | <b>First Named Inventor</b>   | Adnan M.M. Mjalli |
|  |    | <b>Art Unit</b>               | 1614              |
|  |    | <b>Examiner Name</b>          | Unknown           |
| (Use as many sheets as necessary)                        |    | <b>Attorney Docket Number</b> | TTP 2002-08       |
| Sheet  | 12 | of                            | 19                |

| NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials *             | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
| LLS                             | TR-36                 | CROSS KP, "Finding discriminating structural features by reassembling common building blocks." Journal of Medicinal Chemistry, 46:4770-4775 (2003)  |                |
|                                 | TR-37                 | WANG Q, "Fluorescein monophosphates as fluorogenic substrates for protein tyrosine phosphatases." Biochimica Et Biophysica Acta, 1431:14-23 (1999)  |                |
|                                 | TR-38                 | SHIM YS, "Formylchromone derivatives as a novel class of protein tyrosine phosphatase 1B inhibitors." Bioorganic & Medicinal Chemistry Letters, 13:2561-2563 (2003)   |                |
|                                 | TR-39                 | LIU G, "Fragment screening and assembly: a highly efficient approach to a selective and cell active protein tyrosine phosphatase 1B inhibitor." Journal of Medicinal Chemistry, 46:4232-4235 (2003)   |                |
|                                 | TR-40                 | ROMSICKI Y, "Functional characterization and crystal structure of the C215D mutant of protein-tyrosine phosphatase-1B." The Journal of Biological Chemistry, 278:29009-15 (2003)  |                |
|                                 | TR-41                 | PHAN J, "High-Resolution Structure of the Yersinia pestis Protein Tyrosine Phosphatase YopH in Complex with a Phosphotyrosyl Mimetic-Containing Hexapeptide." Biochemistry, 42:13113-13121 (2003)   |                |
|                                 | TR-42                 | XIN Z, "Identification of a monoacid-Based, cell permeable, selective inhibitor of protein tyrosine phosphatase 1B." Bioorganic & Medicinal Chemistry Letters, 13:3947-3950 (2003)  |                |
|                                 | TR-43                 | PUIUS YA, "Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: a paradigm for inhibitor design." Proceedings of the National Academy of Sciences, 94:13420-13425 (1997)  |                |
|                                 | TR-44                 | FUKADA T, "Identification of YB-1 as a regulator of PTP1B expression: implications for regulation of insulin and cytokine signaling." The EMBO Journal, 22:479-493 (2003)   |                |
|                                 | TR-45                 | ELCHEBLY M, "Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene." Science, 283:1544-1548 (1999)  |                |
| LLS                             | TR-46                 | ZABELL AP, "Inhibition studies with rationally designed inhibitors of the human low molecular weight protein tyrosine phosphatase." Bioorganic & Medicinal Chemistry, 12:1867-1880 (2004)   |                |

|                    |                     |                 |            |
|--------------------|---------------------|-----------------|------------|
| Examiner Signature | /Laura L. Stockton/ | Date Considered | 01/18/2007 |
|--------------------|---------------------|-----------------|------------|


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US





PTO/SB/08b(08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

|   |          |                          |                   |
|---|----------|--------------------------|-------------------|
| Substitute for form 1449B/PTO   |          | <b>Complete if Known</b> |                   |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use as many sheets as necessary) |          | Application Number       | 10/777,421        |
|   |          | Filing Date              | 02/04/04          |
|   |          | First Named Inventor     | Adnan M.M. Mjalli |
|   |          | Art Unit                 | 1615              |
|   |          | Examiner Name            | Unknown           |
| Sheet   | 13 of 19 | Attorney Docket Number   | TTP 2002-07       |

| NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials *             | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
| LLS                             | TR-59                 | DOMAN TN, "Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B." Journal of Medicinal Chemistry, 45:2213-2221 (2002)  |                |
|                                 | TR-60                 | PETERS GH, "Molecular dynamics simulations of protein-tyrosine phosphatase 1B. I. ligand-induced changes in the protein motions." Biophysical Journal, 77:505-515 (1999)  |                |
|                                 | TR-81                 | PETERS GH, "Molecular dynamics simulations of protein-tyrosine phosphatase 1B. II. substrate-enzyme interactions and dynamics." Biophysical Journal, 78:2191-2200 (2000)  |                |
|                                 | TR-82                 | MALAMAS MS, "New azolidinediones as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties." Journal of Medicinal Chemistry, 43:995-1010 (2000)  |                |
|                                 | TR-83                 | MALAMAS MS, "Novel benzofuran and benzothiophene biphenyls as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties." Journal of Medicinal Chemistry, 43:1293-1310 (2000)   |                |
|                                 | TR-234                | MEANWELL et al., "Nonprostanoid Prostacyclin Mimetics. 2. 4,5-Diphenyloxazole Derivatives", Journal of Medicinal Chemistry, Vol. 35, pages 3483-3497 (1992)   |                |
|                                 | TR-84                 | GLOVER NR, "Nuclear magnetic resonance and restrained molecular dynamics studies of the interaction of an epidermal growth factor-derived peptide with protein tyrosine phosphatase 1B." Biochemistry, 38:5256-5271 (1999)                                      |                |
|                                 | TR-85                 | LILJEBRIS C, "Oxidation of protein tyrosine phosphatases as a pharmaceutical mechanism of action: a study using 4-hydroxy-3,3-dimethyl-2H-benzo[g]indole-2,5(3H)-dione." The Journal of Pharmacology & Experimental Therapeutics, 309:711-719 (2004)            |                |
|                                 | TR-86                 | VAN MONTFORT RL, "Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B." Nature, 423:773-777 (2003)   |                |
|                                 | TR-87                 | CHEN YT, "Parallel synthesis of a library of bidentate protein tyrosine phosphatase inhibitors based on the alpha-ketoacid motif." Bioorganic & Medicinal Chemistry, 12:3289-3298 (2004)  |                |
| ↓                               | TR-88                 | CHEN YT, "Peptidic alpha-Ketocarboxylic Acids and Sulfonamides as Inhibitors of Protein Tyrosine Phosphatases." Journal of Organic Chemistry, 68:4123-4125 (2003)   |                |
| LLS                             | TR-89                 | TAING M, "Potent and highly selective inhibitors of the protein tyrosine phosphatase 1B" Biochemistry, 38:3793-3803 (1999)  |                |

|                    |                     |                 |            |
|--------------------|---------------------|-----------------|------------|
| Examiner Signature | /Laura L. Stockton/ | Date Considered | 01/18/2007 |
|--------------------|---------------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US



PTO/SB/08b(08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 14 of 19

**Complete if Known**

|                        |                   |
|------------------------|-------------------|
| Application Number     | 10/777,488        |
| Filing Date            | 02/12/04          |
| First Named Inventor   | Adnan M.M. Mjalli |
| Art Unit               | 1614              |
| Examiner Name          | Unknown           |
| Attorney Docket Number | TTP 2002-08       |

**NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials * | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|---------------------|-----------------------|---|----------------|
| LLS                 | TR-70                 | URBANEK, "Potent Reversible Inhibitors of the Protein Tyrosien Phosphatase CD45" Journal of Medical Chemistry, 44: 1777-1793 (2001)   |                |
|                     | TR-71                 | XIN Z, "Potent, selective inhibitors of protein tyrosine phosphatase 1B." Bioorganic & Medicinal Chemistry Letters, 13:1887-1890 (2003)   |                |
|                     | TR-72                 | GUO XL, "Probing the molecular basis for potent and selective protein-tyrosine phosphatase 1B inhibition." The Journal of Biological Chemistry, 277:41014-41022 (2002)  |                |
|                     | TR-73                 | HOOFT VAN HUIJSDUIJNEN R, "Prospects for inhibitors of protein tyrosine phosphatase 1B as antidiabetic drugs." Journal of Medicinal Chemistry, 47:4142-4148 (2004)  |                |
|                     | TR-74                 | LIU G, "Protein tyrosine phosphatase 1B inhibition: opportunities and challenges." Current Medicinal Chemistry, 10:1407-1421 (2003)   |                |
|                     | TR-75                 | JOHNSON TO, "Protein tyrosine phosphatase 1B inhibitors for diabetes" Nature Reviews Drug Discovery, 1:696-709 (2002)   |                |
|                     | TR-76                 | RONDINONE CM, "Protein tyrosine phosphatase 1B reduction regulates adiposity and expression of genes involved in lipogenesis." Diabetes, 51:2405-2411 (2002)  |                |
|                     | TR-77                 | RAMACHANDRAN C, "Protein tyrosine phosphatase 1B: a novel target for type 2 diabetes and obesity." Current Topics in Medicinal Chemistry, 3:749-757 (2003)  |                |
|                     | TR-78                 | ROMSICKI Y, "Protein Tyrosine Phosphatase-1B Dephosphorylation of the Insulin Receptor Occurs in a Perinuclear Endosome Compartment in Human Embryonic Kidney 293 Cells." The Journal of Biological Chemistry, 279:12868-12875 (2004)                           |                |
|                     | TR-79                 | WU ZL, "Protein tyrosine phosphatases are up-regulated and participate in cell death induced by polyglutamine expansion." The Journal of Biological Chemistry, 277:44208-44213 (2002)   |                |
| ↓                   | TR-80                 | ALONSO A, "Protein tyrosine phosphatases in the human genome." Cell, 117:699-711 (2004)   |                |
| LLS                 | TR-81                 | ZHANG ZY, "PROTEIN TYROSINE PHOSPHATASES: Structure and Function, Substrate Specificity, and Inhibitor Development" Annual Review of Pharmacology and Toxicology, 42:209-234 (2002)   |                |

|                    |                     |                 |            |
|--------------------|---------------------|-----------------|------------|
| Examiner Signature | /Laura L. Stockton/ | Date Considered | 01/18/2007 |
|--------------------|---------------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US



PTO/SB/08b(08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

15

of

19

**Complete if Known**

|                        |                   |
|------------------------|-------------------|
| Application Number     | 10/777,488        |
| Filing Date            | 02/12/04          |
| First Named Inventor   | Adnan M.M. Mjalli |
| Art Unit               | 1614              |
| Examiner Name          | Unknown           |
| Attorney Docket Number | TTP 2002-08       |

| NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials *             | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
| LLS                             | TR-82                 | GOLDSTEIN BJ, "Protein-tyrosine phosphatase 1B (PTP1B): a novel therapeutic target for type 2 diabetes mellitus, obesity and related states of insulin resistance." Current Drug Targets - Immune, Endocrine & Metabolic Disorders, 1:265-275 (2001)            |                |
|                                 | TR-83                 | DADKE S; CHERNOFF J, "Protein-Tyrosine Phosphatase 1B as a Potential Drug Target for Obesity" Current Drug Targets - Immune, Endocrine & Metabolic Disorders, 3:299-304 (2003)  |                |
|                                 | TR-84                 | SHIMIZU S, "Protein-tyrosine Phosphatase 1B as New Activator for Hepatic Lipogenesis via Sterol Regulatory Element-binding Protein-1 Gene Expression." The Journal of Biological Chemistry, 278:43095-43101 (2003)  |                |
|                                 | TR-85                 | DADKE S, "Protein-tyrosine phosphatase 1B mediates the effects of insulin on the actin cytoskeleton in immortalized fibroblasts." The Journal of Biological Chemistry, 278:40607-40611 (2003)   |                |
|                                 | TR-86                 | GOLDSTEIN BJ, "Protein-tyrosine phosphatases: emerging targets for therapeutic intervention in type 2 diabetes and related states of insulin resistance" The Journal of Clinical Endocrinology & Metabolism, 87:2474-2480 (2002)                                |                |
|                                 | TR-88                 | ZINKER BA, "PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice." Proceedings of the National Academy of Sciences, 99:11357-11362 (2002)  |                |
|                                 | TR-89                 | WARING JF, "PTP1B antisense-treated mice show regulation of genes involved in lipogenesis in liver and fat." Molecular and Cellular Endocrinology, 203:155-168 (2003)   |                |
|                                 | TR-90                 | TONKS NK, "PTP1B: from the sidelines to the front lines" FEBS Letters, 546:140-148 (2003)   |                |
|                                 | TR-91                 | ROMSICKI Y, "Purification and characterization of T cell protein tyrosine phosphatase reveals significant functional homology to protein tyrosine phosphatase-1B." Archives of Biochemistry and Biophysics, 414:40-50 (2003)                                    |                |
|                                 | TR-92                 | SALMEEN A, "Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate." Nature, 423:769-773 (2003)  |                |
| LLS                             | TR-93                 | GUM RJ, "Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob/ob mice." Diabetes, 52:21-28 (2003)   |                |

Examiner  
Signature

/Laura L. Stockton/

Date  
Considered


01/18/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US



PTO/SB/08b(08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 6 of 19

**Complete if Known**

|                        |                   |
|------------------------|-------------------|
| Application Number     | 10/777,488        |
| Filing Date            | 02/12/04          |
| First Named Inventor   | Adnan M.M. Mjalli |
| Art Unit               | 1614              |
| Examiner Name          | Unknown           |
| Attorney Docket Number | TTP 2002-08       |

**NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials * | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|---------------------|-----------------------|---|----------------|
| LLS                 | TR-94                 | GALIC S, "Regulation of insulin receptor signaling by the protein tyrosine phosphatase TCPTP." Molecular And Cellular Biology, 23:2098-2108 (2003)  |                |
|                     | TR-95                 | HAI FG, "Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatase-1B." The Journal of Biological Chemistry, 278:739-44 (2003)   |                |
|                     | TR-96                 | PETERS GH, "Residue 259 is a key determinant of substrate specificity of protein-tyrosine phosphatases 1B and alpha." The Journal of Biological Chemistry, 275:18201-18209 (2000)   |                |
|                     | TR-97                 | LIU G, "Selective protein tyrosine phosphatase 1B inhibitors: targeting the second phosphotyrosine binding site with non-carboxylic acid-containing ligands." Journal of Medicinal Chemistry, 46:3437-3440 (2003)   |                |
|                     | TR-98                 | MILARSKI KL, "Sequence specificity in recognition of the epidermal growth factor receptor by protein tyrosine phosphatase 1B." The Journal of Biological Chemistry, 268:23634-23639 (1993)  |                |
|                     | TR-99                 | HALAZY S, "Signal Transduction: An Exciting Field of Investigation for Small Molecule Drug Discovery" Molecules, 8:349-358 (2003)   |                |
|                     | TR-100                | BLEASDALE JE, "Small molecule peptidomimetics containing a novel phosphotyrosine bioisostere inhibit protein tyrosine phosphatase 1B and augment insulin action." Biochemistry, 40:5642-5654 (2001)   |                |
|                     | TR-229                | CESCON GR, "Some Properties of Triarylimidazolyl Radicals and Their Dimers" Journal of Organic Chemistry, Vol. 36, No. 16, (1971)   |                |
|                     | TR-101                | XIE J, "Squaric Acids: A New Motif for Designing Inhibitors of Protein Tyrosine Phosphatases " Organic Letters, 6:83-86 (2004)  |                |
|                     | TR-102                | DILLET V, "Stabilization of Charges and Protonation States in the Active Site of the Protein Tyrosine Phosphatases: A Computational Study" Journal of Physical Chemistry B, 104:11321-11333 (2000)  |                |
| ✓                   | TR-103                | IVERSEN LF, "Steric hindrance as a basis for structure-based design of selective inhibitors of protein-tyrosine phosphatases." Biochemistry, 40:14812-14820 (2001)  |                |
| LLS                 | TR-104                | ANDERSEN JN, "Structural and evolutionary relationships among protein tyrosine phosphatase domains." Molecular And Cellular Biology, 21:7117-7138 (2001)  |                |

|                    |                     |                 |            |
|--------------------|---------------------|-----------------|------------|
| Examiner Signature | /Laura L. Stockton/ | Date Considered | 01/18/2007 |
|--------------------|---------------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US



PTO/SB/08b(08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

17

of

19

**Complete If Known**

|                        |                   |
|------------------------|-------------------|
| Application Number     | 10/777,488        |
| Filing Date            | 02/12/04          |
| First Named Inventor   | Adnan M.M. Mjalli |
| Art Unit               | 1614              |
| Examiner Name          | Unknown           |
| Attorney Docket Number | TTP 2002-08       |

**NON PATENT LITERATURE DOCUMENTS**

| Examiner<br>Initials * | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|------------------------|--------------------------|---|----------------|
| LLS                    | TR-105                   | GROVES M, "Structural Basis for Inhibition of the Protein Tyrosine Phosphatase 1B by Phosphotyrosine Peptide Mimetics" Biochemistry, 37:17773-17783 (1998)  |                |
|                        | TR-106                   | SARMIENTO M, "Structural basis of plasticity in protein tyrosine phosphatase 1B substrate recognition" Biochemistry, 39:8171-8179 (2000)  |                |
|                        | TR-107                   | LAU C, "Structure based design of a series of potent and selective non peptidic PTP-1B inhibitors" Bioorganic & Medicinal Chem. Letters, 14: 1043-4048 (2004)   |                |
|                        | TR-108                   | VERSEN LF, "Structure determination of T cell protein-tyrosine phosphatase." The Journal of Biological Chemistry, 277:19982-19990 (2002)  |                |
|                        | TR-109                   | JIA Z, "Structure of protein tyrosine phosphatase 1B in complex with inhibitors bearing two phosphotyrosine mimetics." Journal of Medicinal Chemistry, 44:4584-4594 (2001)  |                |
|                        | TR-110                   | IVERSEN LF, "Structure-based design of a low molecular weight, nonphosphorus, nonpeptide, and highly selective inhibitor of protein-tyrosine phosphatase 1B." The Journal of Biological Chemistry, 275:10300-10307 (2000)                                       |                |
|                        | TR-111                   | LUND IK, "Structure-based design of selective and potent inhibitors of protein-tyrosine phosphatase beta." The Journal of Biological Chemistry, 279:24228-24235 (2004)  |                |
|                        | TR-112                   | SARMIENTO M, "Structure-based discovery of small molecule inhibitors targeted to protein tyrosine phosphatase 1B." Journal of Medicinal Chemistry, 43:148-155 (2000)  |                |
|                        | TR-113                   | WANG J, "Structure-based Prediction of Free Energy Changes of binding of PTP1B Inhibitors" Journal of Computer-Aided Molecular Design, 17:495-513 (2003)  |                |
|                        | TR-114                   | MCCAIN DF, "Suramin derivatives as inhibitors and activators of protein-tyrosine phosphatases." The Journal of Biological Chemistry, 279:14713-14725 (2004)   |                |
|                        | TR-115                   | LILJEBRIS C, "Synthesis and biological activity of a novel class of pyridazine analogues as non-competitive reversible inhibitors of protein tyrosine phosphatase 1B (PTP1B)." Bioorganic & Medicinal Chemistry, 10:3197-3212 (2002)                            |                |
| ✓                      | TR-116                   | LARSEN SD, "Synthesis and biological activity of a novel class of small molecular weight peptidomimetic competitive inhibitors of protein tyrosine phosphatase 1B" Journal of Medicinal Chemistry, 45:598-622 (2002)  |                |
| LLS                    | TR-117                   | THERIEN M, "Synthesis of a novel peptidic photoaffinity probe for the PTP-1B enzyme." Bioorganic & Medicinal Chemistry Letters, 14:2319-2322 (2004)   |                |

Examiner  
Signature

/Laura L. Stockton/

Date  
Considered


01/18/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US



PTO/SB/08b(08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

|   |                        |                          |                   |
|---|------------------------|--------------------------|-------------------|
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use as many sheets as necessary) |                        | <b>Complete if Known</b> |                   |
|   |                        | Application Number       | 10/777,488        |
|   |                        | Filing Date              | 02/12/04          |
|   |                        | First Named Inventor     | Adnan M.M. Mjalli |
|   |                        | Art Unit                 | 1614              |
|   |                        | Examiner Name            | Unknown           |
| Sheet 18 of 19  | Attorney Docket Number | TTP 2002-08              |                   |

| NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials *             | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
| LLS                             | TR-118                | DUFRESNE C, "The development of potent non-peptidic PTP-1B inhibitors." Bioorganic & Medicinal Chemistry Letters, 14:1039-1042 (2004)   |                |
|                                 | TR-119                | LEUNG C, "The difluoromethylenesulfonic acid group as a monoanionic phosphate surrogate for obtaining PTP1B inhibitors." Bioorganic & Medicinal Chemistry, 10:2309-2323 (2002)  |                |
|                                 | TR-120                | MOONEY RA, "The leukocyte common antigen-related protein LAR: candidate PTP for inhibitory targeting." Current Topics in Medicinal Chemistry, 3:809-819 (2003)  |                |
|                                 | TR-122                | TIGANIS T, "The protein-tyrosine phosphatase TCPTP regulates epidermal growth factor receptor-mediated and phosphatidylinositol 3-kinase-dependent signaling." The Journal of Biological Chemistry, 274:27768-27775 (1999)                                      |                |
|                                 | TR-123                | WIDLANSKI TS, "The road less travelled: taming phosphatases." Chemistry & Biology, 4:489-492 (1997)   |                |
|                                 | TR-124                | DUBE N, "The role of protein tyrosine phosphatase 1B in Ras signaling." Proceedings of the National Academy of Sciences, 101:1834-1839 (2004)   |                |
|                                 | TR-125                | ESPANEL X, "The SPOT technique as a tool for studying protein tyrosine phosphatase substrate specificities." Protein Science, 11:2326-2334 (2002)   |                |
|                                 | TR-126                | SCAPIN G, "The structural basis for the selectivity of benzotriazole inhibitors of PTP1B." Biochemistry, 42:11451-11459 (2003)  |                |
|                                 | TR-127                | ASANTE-APPIAH E, "The structure of PTP-1B in complex with a peptide inhibitor reveals an alternative binding mode for bisphosphonates." Biochemistry, 41:9043-9051 (2002)   |                |
| ✓                               | TR-128                | BUKCYNSKA P, "The T-cell protein tyrosine phosphatase is phosphorylated on Ser-304 by cyclin-dependent protein kinases in mitosis." Biochemical Journal, 380:939-949 (2004)   |                |
| LLS                             | TR-129                | RAGAB A, "The tyrosine phosphatase 1B regulates linker for activation of T-cell phosphorylation and platelet aggregation upon FcγRIIIa cross-linking." The Journal of Biological Chemistry, 278:40923-40932 (2003)  |                |

|                    |                     |                 |            |
|--------------------|---------------------|-----------------|------------|
| Examiner Signature | /Laura L. Stockton/ | Date Considered | 01/18/2007 |
|--------------------|---------------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

|   |    |                          |                   |                        |             |
|---|----|--------------------------|-------------------|------------------------|-------------|
| Substitute for form 1449B/PTO   |    | <b>Complete if Known</b> |                   |                        |             |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use as many sheets as necessary) |    | Application Number       | 10/777,488        |                        |             |
|   |    | Filing Date              | 02/12/04          |                        |             |
|   |    | First Named Inventor     | Adnan M.M. Mjalli |                        |             |
|   |    | Art Unit                 | 1614              |                        |             |
|   |    | Examiner Name            | Unknown           |                        |             |
| Sheet   | 19 | of                       | 19                | Attorney Docket Number | TTP 2002-08 |

| NON PATENT LITERATURE DOCUMENTS |                       |  |                |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials *             | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.                        | T <sup>2</sup> |
| LLS                             | TR-130                | ZABOLOTNY JM, "Transgenic Overexpression of Protein-tyrosine Phosphatase 1B in Muscle Causes Insulin Resistance, but Overexpression with Leukocyte Antigen-related Phosphatase Does Not Additively Impair Insulin Action." The Journal of Biological Chemistry, 279:24844-24851 (2004) |                |
|                                 | TR-131                | LEE K, "Tripeptide inhibitors of Yersinia protein-tyrosine phosphatase." Bioorganic & Medicinal Chemistry Letters, 13:2577-2581 (2003)   |                |
|                                 | TR-132                | SIMS C, "Tyrosine phosphatase inhibitors selectively antagonize beta-adrenergic receptor-dependent regulation of cardiac ion channels." Molecular Pharmacology, 58:1213-1221 (2000)  |                |
| LLS                             | TR-133                | ZHU L, "Use of an Anaerobic Chamber Environment for the Assay of Endogenous Cellular Protein-Tyrosine Phosphatase Activities." Biological Procedures Online, 4:1-9 (2002)  |                |
|                                 |                       |  |                |
|                                 |                       |  |                |
|                                 |                       |  |                |
|                                 |                       |  |                |
|                                 |                       |  |                |
|                                 |                       |  |                |
|                                 |                       |  |                |
|                                 |                       |  |                |
|                                 |                       |  |                |

|                    |                     |                 |            |
|--------------------|---------------------|-----------------|------------|
| Examiner Signature | /Laura L. Stockton/ | Date Considered | 01/18/2007 |
|--------------------|---------------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US